Biodefense Market Size By Product (Vaccines {Anthrax, Smallpox, Botulism}, Biothreat Detection Devices {Samplers, Detectors/Triggering Devices, Identifiers, Assays And Reagents}), Industry Analysis Report, Regional Outlook, Application Potential, Competit

Biodefense Market Size By Product (Vaccines {Anthrax, Smallpox, Botulism}, Biothreat Detection Devices {Samplers, Detectors/Triggering Devices, Identifiers, Assays And Reagents}), Industry Analysis Report, Regional Outlook, Application Potential, Competitive Market Share & Forecast, 2018 - 2024

Biodefense Market to exceed USD 17 billion by 2024 as per a new research report.

Growing bioterrorism and research for early development of medical countermeasures against chemical threats will drive biodefense market over the forecast timeframe. Increasing use of bio-agents coupled with rising need of biosecurity should fuel the industry growth. Increasing threats of radiation exposure, infectious diseases and chemicals coupled with lethal pathogens, such as avian influenza will stimulate global biodefense market.

Furthermore, focus on developing vaccines, drugs, and diagnostics test for disease agents and developing broad‐spectrum therapies effective against entire classes of pathogens using cultured proteomic and genomic platforms should propel industry growth. Biodefense market growth may be hindered by increasing bioterrorism agents with growing terror and low penetration in developing and underdeveloped countries.

Anthrax market will witness significant growth during the forecast period due to increasing product development activities for inhalational anthrax animal models and efficacy assessment of vaccines and therapeutics in rabbits.

U.S. biodefense market will witness robust growth over forecast period owing to increasing research and primary development of medical countermeasures against radiation exposure and infectious diseases. NBACC facility offering intelligence assessments, preparedness planning, response, emerging threat characterization and bio-forensic analysis will drive business growth.

UK biodefense market share accounted for largest regional revenue share due to increasing defensive measures used against biological agents that continue multiplying in the affected individual, area or surroundings will fuel business growth.

Japan biodefense market should grow at a significant rate over the forecast period due to increasing number of biodefense laboratories and R&D expenditure coupled with several initiatives for bio-safety promotion taken by the government.

Increasing government initiatives for controlling diseases coupled with low cost of producing biological defense agents will drive Brazil biodefense market. Furthermore, increasing technological advancements should fuel business to grow at a substantial rate.

South Africa biodefense market is growing at a significant rate owing to high importance on developing policy at continental or regional level for biodefense. Improved research infrastructure including BSL 4 research laboratory reporting study on endemic diseases in animal with no cure should propel the industry share.

Biodefense aims to prevent the development and use of biological weapons as well as lessen the human suffering occurs if prevention fails. Increasing government initiatives towards protection against potential deadly or devastating impact on a vulnerable population will boost the industry growth. The business should witness high growth owing to research providing the basis for developing medical products and strategies to prevent, diagnose and treat a wide range of infectious diseases.

Key industry players are Bavarian-Nordic, Cleveland BioLabs, Emergent Biosolutions, Xoma, SIGA Technologies and PharmaAthene. Industry participants are securing their market position by increasing their focus on R&D activities to develop new and effective bio-safety medicines and vaccines.


Chapter 1. Methodology
1.1. Methodology
1.2. Market definitions
1.3. Forecast parameters
1.4. Data sources
1.4.1. Secondary
1.4.1.1. Paid sources
1.4.1.2. Unpaid sources
1.4.2. Primary
Chapter 2. Executive Summary
2.1. Biodefense industry 360 degree synopsis, 2013 - 2024
2.1.1. Business trends
2.1.2. Product trends
2.1.3. Regional trends
Chapter 3. Biodefense Industry Insights
3.1. Industry segmentation
3.2. Industry landscape, 2013 - 2024
3.3. Industry impact forces
3.3.1. Growth drivers
3.3.1.1. Growing investments by government in R&D in North America & Europe
3.3.1.2. Favorable government initiatives in Asia Pacific and Latin America
3.3.1.3. Technological advancements in biotechnology sector in North America and Europe
3.3.2. Industry pitfalls and challenges
3.3.2.1. Low R&D funding by government in underdeveloped regions
3.4. Growth potential analysis
3.4.1. By product
3.5. Competitive landscape, 2017
3.5.1. Strategy dashboard
3.6. Porter's analysis
3.7. PESTEL analysis
Chapter 4. Biodefense Market, By Product
4.1. Key segment trends
4.2. Vaccines
4.2.1. Market size, by region, 2013-2024 (USD Million)
4.2.2. Anthrax
4.2.2.1. Market size, by region, 2013-2024 (USD Million)
4.2.3. Smallpox
4.2.3.1. Market size, by region, 2013-2024 (USD Million)
4.2.4. Botulism
4.2.4.1. Market size, by region, 2013-2024 (USD Million)
4.2.5. Others
4.2.5.1. Market size, by region, 2013-2024 (USD Million)
4.3. Biothreat detection devices
4.3.1. Market size, by region, 2013-2024 (USD Million)
4.3.2. Samplers
4.3.2.1. Market size, by region, 2013-2024 (USD Million)
4.3.3. Detectors/triggering devices
4.3.3.1. Market size, by region, 2013-2024 (USD Million)
4.3.4. Identifiers
4.3.4.1. Market size, by region, 2013-2024 (USD Million)
4.3.5. Assays and reagents
4.3.5.1. Market size, by region, 2013-2024 (USD Million)
Chapter 5. Biodefense Market, By Region
5.1. Key regional trends
5.2. North America
5.2.1. Market size, by country, 2013 - 2024 (USD Million)
5.2.2. Market size, by product, 2013 - 2024 (USD Million)
5.2.3. U.S.
5.2.3.1. Market size, by product, 2013 - 2024 (USD Million)
5.2.4. Canada
5.2.4.1. Market size, by product, 2013 - 2024 (USD Million)
5.3. Europe
5.3.1. Market size, by country, 2013 - 2024 (USD Million)
5.3.2. Market size, by product, 2013 - 2024 (USD Million)
5.3.3. Germany
5.3.3.1. Market size, by product, 2013 - 2024 (USD Million)
5.3.4. France
5.3.4.1. Market size, by product, 2013 - 2024 (USD Million)
5.3.5. UK
5.3.5.1. Market size, by product, 2013 - 2024 (USD Million)
5.3.6. Italy
5.3.6.1. Market size, by product, 2013 - 2024 (USD Million)
5.3.7. Spain
5.3.7.1. Market size, by product, 2013 - 2024 (USD Million)
5.4. Asia Pacific
5.4.1. Market size, by country, 2013 - 2024 (USD Million)
5.4.2. Market size, by product, 2013 - 2024 (USD Million)
5.4.3. China
5.4.3.1. Market size, by product, 2013 - 2024 (USD Million)
5.4.4. Japan
5.4.4.1. Market size, by product, 2013 - 2024 (USD Million)
5.4.5. India
5.4.5.1. Market size, by product, 2013 - 2024 (USD Million)
5.4.6. Australia
5.4.6.1. Market size, by product, 2013 - 2024 (USD Million)
5.4.7. South Korea
5.4.7.1. Market size, by product, 2013 - 2024 (USD Million)
5.5. Latin America
5.5.1. Market size, by country, 2013 - 2024 (USD Million)
5.5.2. Market size, by product, 2013 - 2024 (USD Million)
5.5.3. Brazil
5.5.3.1. Market size, by product, 2013 - 2024 (USD Million)
5.5.4. Mexico
5.5.4.1. Market size, by product, 2013 - 2024 (USD Million)
5.5.5. Argentina
5.5.5.1. Market size, by product, 2013 - 2024 (USD Million)
5.6. MEA
5.6.1. Market size, by country, 2013 - 2024 (USD Million)
5.6.2. Market size, by product, 2013 - 2024 (USD Million)
5.6.3. South Africa
5.6.3.1. Market size, by product, 2013 - 2024 (USD Million)
5.6.4. Saudi Arabia
5.6.4.1. Market size, by product, 2013 - 2024 (USD Million)
5.6.5. UAE
5.6.5.1. Market size, by product, 2013 - 2024 (USD Million)
5.6.6. Israel
5.6.6.1. Market size, by product, 2013 - 2024 (USD Million)
Chapter 6. Company Profiles
6.1. Achaogen
6.1.1. Business overview
6.1.2. Financial data
6.1.3. Product landscape
6.1.4. Strategic outlook
6.1.5. SWOT analysis
6.2. Alnylam Pharmaceuticals
6.2.1. Business overview
6.2.2. Financial data
6.2.3. Product landscape
6.2.4. Strategic outlook
6.2.5. SWOT analysis
6.3. Altimmune
6.3.1. Business overview
6.3.2. Financial data
6.3.3. Product landscape
6.3.4. Strategic outlook
6.3.5. SWOT analysis
6.4. AISense
6.4.1. Business overview
6.4.2. Financial data
6.4.3. Product landscape
6.4.4. Strategic outlook
6.4.5. SWOT analysis
6.5. Alexeter Technologies, LLC
6.5.1. Business overview
6.5.2. Financial data
6.5.3. Product landscape
6.5.4. Strategic outlook
6.5.5. SWOT analysis
6.6. ANP Technologies
6.6.1. Business overview
6.6.2. Financial data
6.6.3. Product landscape
6.6.4. Strategic outlook
6.6.5. SWOT analysis
6.7. Bavarian Nordic
6.7.1. Business overview
6.7.2. Financial data
6.7.3. Product landscape
6.7.4. Strategic outlook
6.7.5. SWOT analysis
6.8. BBI Detection
6.8.1. Business overview
6.8.2. Financial data
6.8.3. Product landscape
6.8.4. Strategic outlook
6.8.5. SWOT analysis
6.9. Cleveland BioLabs, Inc.
6.9.1. Business overview
6.9.2. Financial data
6.9.3. Product landscape
6.9.4. Strategic outlook
6.9.5. SWOT analysis
6.10. Dynavax Technologies, Inc.
6.10.1. Business overview
6.10.2. Financial data
6.10.3. Product landscape
6.10.4. Strategic outlook
6.10.5. SWOT analysis
6.11. DynPort Vaccine Company LLC
6.11.1. Business overview
6.11.2. Financial data
6.11.3. Product landscape
6.11.4. Strategic outlook
6.11.5. SWOT analysis
6.12. Elusys Therapeutics
6.12.1. Business overview
6.12.2. Financial data
6.12.3. Product landscape
6.12.4. Strategic outlook
6.12.5. SWOT analysis
6.13. Emergent BioSolutions
6.13.1. Business overview
6.13.2. Financial data
6.13.3. Product landscape
6.13.4. Strategic outlook
6.13.5. SWOT analysis
6.14. Ichor Medical Systems, Inc.
6.14.1. Business overview
6.14.2. Financial data
6.14.3. Product landscape
6.14.4. Strategic outlook
6.14.5. SWOT analysis
6.15. Nanotherapeutics Inc.
6.15.1. Business overview
6.15.2. Financial data
6.15.3. Product landscape
6.15.4. Strategic outlook
6.15.5. SWOT analysis
6.16. New Horizons Diagnostics
6.16.1. Business overview
6.16.2. Financial data
6.16.3. Product landscape
6.16.4. Strategic outlook
6.16.5. SWOT analysis
6.17. PathSensors
6.17.1. Business overview
6.17.2. Financial data
6.17.3. Product landscape
6.17.4. Strategic outlook
6.17.5. SWOT analysis
6.18. Research International
6.18.1. Business overview
6.18.2. Financial data
6.18.3. Product landscape
6.18.4. Strategic outlook
6.18.5. SWOT analysis
6.19. SIGA Technologies
6.19.1. Business overview
6.19.2. Financial data
6.19.3. Product landscape
6.19.4. Strategic outlook
6.19.5. SWOT analysis
Data Tables
TABLE 1. Biodefense industry 360 degree synopsis, 2013 - 2024
TABLE 2. Biodefense market, 2013-2024 (USD Mn)
TABLE 3. Biodefense market, by product, 2013-2024 (USD Mn)
TABLE 4. Biodefense market, by application, 2013-2024 (USD Mn)
TABLE 5. Biodefense market, by end-user 2013-2024 (USD Mn)
TABLE 6. Biodefense market, by region, 2013-2024 (USD Mn)
TABLE 7. Industry impact forces
TABLE 8. Vaccines market size, by region, 2013-2024 (USD Mn)
TABLE 9. Anthrax market size, by region, 2013-2024 (USD Mn)
TABLE 10. Smallpox market size, by region, 2013-2024 (USD Mn)
TABLE 11. Botulism market size, by region, 2013-2024 (USD Mn)
TABLE 12. Others market size, by region, 2013-2024 (USD Mn)
TABLE 13. Biothreat detection devices market size, by region, 2013-2024 (USD Mn)
TABLE 14. Samplers market size, by region, 2013-2024 (USD Mn)
TABLE 15. Detectors/triggering devices market size, by region, 2013-2024 (USD Mn)
TABLE 16. Identifiers market size, by region, 2013-2024 (USD Mn)
TABLE 17. Assays and reagents market size, by region, 2013-2024 (USD Mn)
TABLE 18. North America biodefense market size, by country, 2013-2024 (USD Mn)
TABLE 19. North America biodefense market size, by product, 2013-2024 (USD Mn)
TABLE 20. U.S. biodefense market size, by product, 2013-2024 (USD Mn)
TABLE 21. Canada biodefense market size, by product, 2013-2024 (USD Mn)
TABLE 22. Europe biodefense market size, by country, 2013-2024 (USD Mn)
TABLE 23. Europe biodefense market size, by product, 2013-2024 (USD Mn)
TABLE 24. Germany biodefense market size, by product, 2013-2024 (USD Mn)
TABLE 25. UK biodefense market size, by product, 2013-2024 (USD Mn)
TABLE 26. France biodefense market size, by product, 2013-2024 (USD Mn)
TABLE 27. Spain biodefense market size, by product, 2013-2024 (USD Mn)
TABLE 28. Italy biodefense market size, by product, 2013-2024 (USD Mn)
TABLE 29. Asia Pacific biodefense market size, by country, 2013-2024 (USD Mn)
TABLE 30. Asia Pacific biodefense market size, by product, 2013-2024 (USD Mn)
TABLE 31. Japan biodefense market size, by product, 2013-2024 (USD Mn)
TABLE 32. China biodefense market size, by product, 2013-2024 (USD Mn)
TABLE 33. India biodefense market size, by product, 2013-2024 (USD Mn)
TABLE 34. Australia biodefense market size, by product, 2013-2024 (USD Mn)
TABLE 35. South Korea biodefense market size, by product, 2013-2024 (USD Mn)
TABLE 36. Latin America biodefense market size, by country, 2013-2024 (USD Mn)
TABLE 37. Latin America biodefense market size, by product, 2013-2024 (USD Mn)
TABLE 38. Brazil biodefense market size, by product, 2013-2024 (USD Mn)
TABLE 39. Mexico biodefense market size, by product, 2013-2024 (USD Mn)
TABLE 40. Argentina biodefense market size, by product, 2013-2024 (USD Mn)
TABLE 41. MEA biodefense market size, by country, 2013-2024 (USD Mn)
TABLE 42. MEA biodefense market size, by product, 2013-2024 (USD Mn)
TABLE 43. South Africa biodefense market size, by product, 2013-2024 (USD Mn)
TABLE 44. Saudi Arabia biodefense market size, by product, 2013-2024 (USD Mn)
TABLE 45. UAE biodefense market size, by product, 2013-2024 (USD Mn)
TABLE 46. Israel biodefense market size, by product, 2013-2024 (USD Mn)
Charts & Figures
FIG 1. Industry segmentation
FIG 2. Global biodefense market, 2013 - 2024 (USD Mn)
FIG 3. Growth potential analysis, by product
FIG 4. Porter's analysis
FIG 5. Strategy dashboard
FIG 6. PESTEL analysis

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook